Juniper Pharmaceuticals (JNP) vs. Opko Health (OPK) Head-To-Head Analysis
Juniper Pharmaceuticals (NASDAQ: JNP) and Opko Health (NASDAQ:OPK) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, profitability, risk, analyst recommendations, dividends and institutional ownership.
Institutional & Insider Ownership
36.4% of Juniper Pharmaceuticals shares are owned by institutional investors. Comparatively, 22.9% of Opko Health shares are owned by institutional investors. 7.2% of Juniper Pharmaceuticals shares are owned by insiders. Comparatively, 40.2% of Opko Health shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
This table compares Juniper Pharmaceuticals and Opko Health’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Valuation & Earnings
This table compares Juniper Pharmaceuticals and Opko Health’s gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Juniper Pharmaceuticals||$54.57 million||1.01||$5.95 million||$0.59||8.64|
|Opko Health||$1.22 billion||2.36||-$25.08 million||($0.19)||-27.11|
Juniper Pharmaceuticals has higher earnings, but lower revenue than Opko Health. Opko Health is trading at a lower price-to-earnings ratio than Juniper Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
This is a summary of current recommendations for Juniper Pharmaceuticals and Opko Health, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Juniper Pharmaceuticals currently has a consensus price target of $23.00, indicating a potential upside of 350.98%. Opko Health has a consensus price target of $14.81, indicating a potential upside of 187.62%. Given Juniper Pharmaceuticals’ higher possible upside, research analysts plainly believe Juniper Pharmaceuticals is more favorable than Opko Health.
Volatility & Risk
Juniper Pharmaceuticals has a beta of 0.03, suggesting that its share price is 97% less volatile than the S&P 500. Comparatively, Opko Health has a beta of 1.81, suggesting that its share price is 81% more volatile than the S&P 500.
Juniper Pharmaceuticals beats Opko Health on 7 of the 13 factors compared between the two stocks.
Juniper Pharmaceuticals Company Profile
Juniper Pharmaceuticals, Inc. is a women’s health therapeutics company. The Company is focused on developing therapeutics that address unmet medical needs in women’s health. It operates in two segments: product and service. The product segment is engaged in manufacturing and supplying CRINONE, the Company’s commercialized product. The service segment includes product development, clinical trial manufacturing, and advanced analytical and consulting services, as well as characterizing and developing its pharmaceutical product candidates. The Company’s pipeline of proprietary products includes JNP-0101, JNP-0201 and JNP-0301. JNP-0101 is developed to deliver oxybutynin for the treatment of overactive bladder in women. JNP-0201 is being designed to deliver natural hormones locally to vaginal tissue. JNP-0301 is being developed for the prevention of pre-term birth in women with a short cervical length. CRINONE is developed as a progesterone gel.
Opko Health Company Profile
OPKO Health, Inc. is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations. Through Bio-Reference, it operates laboratory divisions, such as Bio-Reference, GenPath (Oncology), GenPath (Women’s Health), GeneDx and Laboratorio Bueno Salud. As of December 31, 2016, it had one commercial stage pharmaceutical product and several pharmaceutical compounds and technologies in various stages of research and development for a range of indications and conditions, including Renal Products, Biologics, hGH-CTP, Factor VII, Oxyntomodulin, active pharmaceutical ingredients, Oligonucleotide Therapeutics, NK-1 Program, Asthma and chronic obstructive pulmonary disease.
Receive News & Ratings for Juniper Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juniper Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.